Celgene International Sárl (CELG) Release: Analyses of MPACT Trial Evaluating ABRAXANE® Combination Therapy for the Treatment of Advanced Pancreatic Cancer Presented at American Society of Clinical Oncology 2013
6/3/2013 10:51:09 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG), announced several analyses of a phase III clinical trial of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in previously untreated patients with advanced pancreatic cancer. The data were presented at the American Society of Clinical Oncology (ASCO) 2013 annual meeting in Chicago.
Help employers find you! Check out all the jobs and post your resume.
comments powered by